Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Treatment Regimen
100%
Hodgkin Lymphoma
100%
Vertebral Bone Quality
100%
Bone Mineral Density
83%
Bone Mineral Density Loss
50%
Lymphoma Patients
50%
Osteopenia
33%
Bleomycin
33%
Adriamycin
33%
Steroid Dose
33%
Multivariate Analysis
16%
Risk Factors
16%
Young Age
16%
Life Expectancy
16%
Age at Diagnosis
16%
Significant Risk Factors
16%
Individuals at Risk
16%
Newly Diagnosed
16%
Long-term Treatment
16%
Therapeutic Modalities
16%
Oncovin
16%
Cyclophosphamide
16%
Gonadotoxic
16%
Vinblastine
16%
Chemotherapy Regimen
16%
Steroid Switch
16%
Procarbazine
16%
Hydrocortisone
16%
Escalated BEACOPP
16%
Dacarbazine
16%
Density Dynamics
16%
Etoposide
16%
Prednisone
16%
PET Scan
16%
Treatment Side Effects
16%
Equivalent Dose
16%
Density Reduction
16%
Therapy-related
16%
Medicine and Dentistry
Hodgkin's Lymphoma
100%
Bone Density
100%
Osteopenia
22%
Prevalence
11%
Side Effect
11%
Life Expectancy
11%
Multivariate Analysis
11%
Therapeutic Modality
11%
Doxorubicin
11%
Positron Emission Tomography-Computed Tomography
11%
BEACOPP
11%
Cyclophosphamide
11%
Vincristine Sulfate
11%
Prednisone
11%
Procarbazine
11%
Adriamycin Bleomycin Vinblastine Dacarbazine
11%
Hydrocortisone
11%
Equivalent Dose
11%
Bleomycin
11%
Etoposide
11%
Chemotherapy
11%
Pharmacology, Toxicology and Pharmaceutical Science
Hodgkin Disease
100%
Doxorubicin
33%
Osteopenia
33%
Bleomycin
33%
Side Effect
16%
Prevalence
16%
Chemotherapy
16%
Hydrocortisone
16%
Vincristine Sulfate
16%
Life Expectancy
16%
Vinblastine
16%
Etoposide
16%
Cyclophosphamide
16%
Dacarbazine
16%
Prednisone
16%
Procarbazine
16%
Polyethylene Terephthalate
16%
Immunology and Microbiology
Bone Density
100%
Prevalence
11%
Dynamics
11%
X-Ray Computed Tomography
11%
Prednisone
11%
Positron Emission Tomography-Computed Tomography
11%
Cyclophosphamide
11%
Life Expectancy
11%
Cortisol
11%